Evidence map›Paper›PMID 27326003›Full record

ArticleHeart Asia2011

Risk-factor profile, drug usage and cardiovascular events within a year in patients with and at high risk of atherothrombosis recruited from Asia as compared with those recruited from non-Asian regions: a substudy of the REduction of Atherothrombosis for Continued Health (REACH) registry.

S Goto, Y Ikeda, J C N Chan, P W F Wilson, T Cheng Yeo, C S Liau, M T Abola, G Salette, P G Steg, D L Bhatt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heart Asia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Safety of antithrombotic therapy in East Asian patients.Internal and emergency medicine · 2021
    Review
  3. Article
  4. Ethnic Differences in Oral Antithrombotic Therapy.Korean circulation journal · 2020
    Review
  5. Article
  6. Atherosclerotic Cardiovascular Risk in Japan.Japanese clinical medicine · 2017
    Review
  7. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2015
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

S GotoDepartment of Medicine (Cardiology), Tokai University School of Medicine, Isehara, Japan.
Y IkedaDepartment of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan.
J C N ChanDepartment of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
P W F WilsonEmory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA, USA.
T Cheng YeoDepartment of General Medicine, National University Hospital, Singapore.
C S LiauDepartment of Cardiology, Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
M T AbolaSection of Vascular Medicine, Division of Clinical Cardiology, Philippine Heart Center, Quezon City, Philippines.
G SaletteSanofi-Aventis, Paris, France.
P G StegDepartment of Cardiology, Hôpital Bichat-Claude Bernard, Université Paris, Paris, France.
D L Bhatt10VA Boston Healthcare System and Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo clarify the differences in the baseline characteristics, prevalence and incidence of atherothrombosis in patients recruited from Asia versus non-Asian regions.

designInternational Prospective Cohort Study.

settingRegion focused substudy. PATIENTS: The Reduction of Atherothrombosis for Continued Health (REACH) Registry recruited 68 236 stable outpatients with established atherothrombosis or ≥3 atherothrombotic risk factors from 44 countries.

interventionsNo intervention.

main outcome measuresRisk factors, use of medications, vascular disease bed location, and 1-year cardiovascular (CV) outcomes (CV death, myocardial infarction, stroke).

resultsThe percentages of patients recruited with CVD (Cerebrovascular Disease) were higher in Asia (41.0%) than in non-Asian regions (25.1%) (p<0.0001). The prevalence of diabetes mellitus was higher in Asia (46.6%) than in non-Asian regions (43.3%) (p<0.0001) despite the former having a lower body mass index (BMI) (24.4±3.9 vs 28.8±5.6) (p<0.0001). The combined endpoint of CV death/myocardial infarction/stroke of patients recruited from non-Asian regions of 4.38% (95% CI 4.20 to 4.56) is equivalent to those from the Asian region excluding Japan of 4.65% (95% CI 4.04 to 5.25), but that is significantly lower in patients recruited from Japan of 3.40% (95% CI 2.76 to 4.04, p<0.05).

conclusionsThere is a higher prevalence of CVD and higher prevalence of diabetus mellitus with lower body mass index in patients recruited from the Asian region as compared those recruited from non-Asian regions. The CV event rate in patients recruited from non-Asian regions is equivalent to that of patients recruited from the Asian region excluding Japan, but significantly lower in patients recruited from Japan.

Indexed as

atherosclerosisAtherothrombosisepidemiologygeographic variationmortalityoutcomesplateletsrisk factorthrombosis

Identifiers

PMID27326003
PMCPMC4898548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.